| Literature DB >> 35408631 |
Marta Kus1,2, Klaudia Gorniak2, Piotr Czaklosz2, Anna Olejnik3, Paulina Skupin-Mrugalska4, Izabela Ibragimow2, Hanna Piotrowska-Kempisty1,5.
Abstract
Perindopril arginine (PA) as an angiotensin-converting enzyme (ACE) inhibitor is widely used in cardiovascular diseases, especially in systemic hypertension and heart failure. Although the pharmacokinetics of PA are well documented, there is no available detailed data on its permeation in in vitro conditions. The present study aimed to assess the transport of PA across both biological membranes and artificial biomimetic ones. For the determination of PA transport, the Caco-2 cell line was selected as a reliable in vitro model of gastrointestinal biological barriers. Additionally, a novel 96-well plate with phospholipid membrane PermeaPad was used to evaluate the transport of PA by passive diffusion. We confirmed that PA is relatively poorly permeable across the Caco-2 monolayer. The permeability results obtained from the non-cell-based model demonstrated higher transport of PA as compared to that of Caco-2. Thus, PA transport across the biological membranes might be suggested to be regulated by the membrane transporters.Entities:
Keywords: Caco-2 monolayer; PermeaPad® 96-well plate; intestinal absorption; perindopril arginine; permeability; simple diffusion
Mesh:
Substances:
Year: 2022 PMID: 35408631 PMCID: PMC9000469 DOI: 10.3390/molecules27072232
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The viability of the Caco-2 cell line treated with PA and CAF. Results of the three independent replicates are presented as the mean ± SD. Acceptance criterion for the cell viability exposed for different compounds concentration has been established as 95% (red line).
Figure 2Change in the transepithelial electrical resistance (TEER) over time during Caco-2 cell culture on membranes directed towards the formation of the integral intestinal epithelium. Results of the three independent replicates are presented as the mean ± SD.
Figure 3Kinetics curves of perindopril arginine (PA) (A) and caffeine (CAF) (B) transport across the Caco-2 monolayer. The experimentally (◊) and theoretically (······) determined “cumulative fraction transported” of the compounds versus time transport. PA transport was analyzed at the initial concentrations of 2.0 mg/mL and 1.0 mg/mL. The initial concentration of CAF was established at 0.5 mg/mL.
Apparent permeability coefficients (Papp) of perindopril arginine (PA) and caffeine (CAF) measured through Caco-2 monolayer. Results are reported as an average and standard deviation (n = 3).
| Substance | Concentration (mg/mL) | Papp × 10−6 (cm/s) | Compound Permeability |
|---|---|---|---|
| PA | 2.0 | 1.94 ± 0.96 | low |
| PA | 1.0 | 0.72 ± 0.04 | low |
| CAF | 0.5 | 126.5 ± 2.4 | high |
Figure 4Apparent permeability coefficients (Papp) of perindopril arginine (PA), caffeine (CAF) and naftidrofuryl oxalate (NF) determined in the PermeaPad barrier in pH 6.8 and 7.4. Compounds’ transports were analyzed at the initial concentrations of 2.0 mg/mL and 1.5 mg/mL for PA, 0.5 mg/mL for CAF, and 0.2 mg/mL and 0.125 mg/mL for NF. Results are reported as an average and standard deviation (n = 3).
Figure 5Kinetics curves of perindopril arginine (PA), caffeine (CAF) and naftidrofuryl oxalate (NF) transport across the PermeaPad barrier. The experimentally (◊) and theoretically (······) determined “cumulative fraction transported” of compounds versus time transport. Compounds’ concentrations in donor compartments were established at 2.0 mg/mL (A) and 1.5 mg/mL (B) for PA, 0.5 mg/mL for CAF (C), and 0.2 mg/mL (D) and 0.125 mg/mL (E) for NF.
Physicochemical properties of compounds.
| Substance | Chemical Formula | Molecular Weight (MW) | pKa | logP | Reference |
|---|---|---|---|---|---|
| PA | C25H46N6O7 | 542.7 | 3.17 (strongest acid) | 0.65 | internal data |
| CAF | C8H46N6O7 | 194.2 | 14 | 0.07 | PubChem [ |
| NF | C26H35NO7 | 473.6 | 4.1 | 1.98 | internal data |